Meningococcal Disease Epidemiology in Australia 10 Years After Implementation of a National Conjugate Meningococcal C Immunization Programme

Overview

Journal Epidemiol Infect

Publisher Cambridge University Press

Specialties Infectious Diseases
Public Health

Date 2016 Apr 21

PMID 27094814

Citations 13

Authors

G L Lawrence

H Wang

M Lahra

R Booy

P B McIntyre

Affiliations

Soon will be listed here.

Abstract

Australia implemented conjugate meningococcal C immunization in 2003 with a single scheduled dose at age 12 months and catch-up for individuals aged 2-19 years. Several countries have recently added one or more booster doses to their programmes to maintain disease control. Australian disease surveillance and vaccine coverage data were used to assess longer term vaccine coverage and impact on invasive serogroup C disease incidence and mortality, and review vaccine failures. Coverage was 93% in 1-year-olds and 70% for catch-up cohorts. In 10 years, after adjusting for changes in diagnostic practices, population invasive serogroup C incidence declined 96% (95% confidence interval 94-98) to 0·4 and 0·6 cases/million in vaccinated and unvaccinated cohorts, respectively. Only three serogroup C deaths occurred in 2010-2012 vs. 68 in 2000-2002. Four (<1/million doses) confirmed vaccine failures were identified in 10 years with no increasing trend. Despite published evidence of waning antibody over time, an ongoing single dose of meningococcal C conjugate vaccine in the second year of life following widespread catch-up has resulted in near elimination of serogroup C disease in all age groups without evidence of vaccine failures in the first decade since introduction. Concurrently, serogroup B incidence declined independently by 55%.

Citing Articles

Meningococcal C Disease Outbreak Caused by Multidrug-Resistant Neisseria meningitidis, Fiji.

Getahun Strobel A, Sahukhan A, Ratu A, Kailawadoko J, Koroituku I, Singh S Emerg Infect Dis. 2024; 31(1):32-40.

PMID: 39714270 PMC: 11682797. DOI: 10.3201/eid3101.240476.

Genomic Surveillance of Invasive Meningococcal Disease During a National MenW Outbreak in Australia, 2017-2018.

Sotheran E, Lane C, Horan K, Stevens K, Guglielmino C, Bradbury S Open Forum Infect Dis. 2024; 11(6):ofae249.

PMID: 38854393 PMC: 11161896. DOI: 10.1093/ofid/ofae249.

Preventing invasive meningococcal disease in early infancy.

Presa J, Serra L, Weil-Olivier C, York L Hum Vaccin Immunother. 2022; 18(5):1979846.

PMID: 35482946 PMC: 9196819. DOI: 10.1080/21645515.2021.1979846.

The epidemiology and outcomes of central nervous system infections in Far North Queensland, tropical Australia; 2000-2019.

Gora H, Smith S, Wilson I, Preston-Thomas A, Ramsamy N, Hanson J PLoS One. 2022; 17(3):e0265410.

PMID: 35312713 PMC: 8936475. DOI: 10.1371/journal.pone.0265410.

High coverage of diverse invasive meningococcal serogroup B strains by the 4-component vaccine 4CMenB in Australia, 2007-2011: Concordant predictions between MATS and genetic MATS.

Tozer S, Smith H, Whiley D, Borrow R, Boccadifuoco G, Medini D Hum Vaccin Immunother. 2021; 17(9):3230-3238.

PMID: 33847225 PMC: 8381844. DOI: 10.1080/21645515.2021.1904758.

References

Donovan H, Bedford H . Immunisation: changes in the UK for children and young people. Nurs Child Young People. 2013; 25(9):16-20. DOI: 10.7748/ncyp2013.11.25.9.16.e466. View

ORyan M, Stoddard J, Toneatto D, Wassil J, Dull P . A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs. 2013; 74(1):15-30. PMC: 3890039. DOI: 10.1007/s40265-013-0155-7. View

Borrow R, Abad R, Trotter C, van der Klis F, Vazquez J . Effectiveness of meningococcal serogroup C vaccine programmes. Vaccine. 2013; 31(41):4477-86. DOI: 10.1016/j.vaccine.2013.07.083. View

Rashid H, Booy R . Passive smoking, invasive meningococcal disease and preventive measures: a commentary. BMC Med. 2012; 10:160. PMC: 3568012. DOI: 10.1186/1741-7015-10-160. View

Halperin S, Bettinger J, Greenwood B, Harrison L, Jelfs J, Ladhani S . The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2011; 30 Suppl 2:B26-36. DOI: 10.1016/j.vaccine.2011.12.032. View

Passmore E, Ferson M, Tobin S . EpiReview: Meningococcal disease in NSW, 1991-2011: trends in relation to meningococcal C vaccination. N S W Public Health Bull. 2013; 24(3):119-24. DOI: 10.1071/NB12121. View

Trotter C, Ramsay M . Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccines. FEMS Microbiol Rev. 2006; 31(1):101-7. DOI: 10.1111/j.1574-6976.2006.00053.x. View

MacNeil J, Cohn A, Zell E, Schmink S, Miller E, Clark T . Early estimate of the effectiveness of quadrivalent meningococcal conjugate vaccine. Pediatr Infect Dis J. 2011; 30(6):451-5. DOI: 10.1097/INF.0b013e31820a8b3c. View

Campbell H, Borrow R, Salisbury D, Miller E . Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine. 2009; 27 Suppl 2:B20-9. DOI: 10.1016/j.vaccine.2009.04.067. View

10.

Snape M, Kelly D, Lewis S, Banner C, Kibwana L, Moore C . Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ. 2008; 336(7659):1487-91. PMC: 2440906. DOI: 10.1136/bmj.39563.545255.AE. View

11.

De Wals P, Deceuninck G, Lefebvre B, Boulianne N, De Serres G . Effectiveness of serogroup C meningococcal conjugate vaccine: a 7-year follow-up in Quebec, Canada. Pediatr Infect Dis J. 2011; 30(7):566-9. DOI: 10.1097/INF.0b013e31820e8638. View

12.

Cohen N . Introduction of the National Meningococcal C Vaccination Program. Commun Dis Intell Q Rep. 2003; 27(2):161-2. View

13.

de Whalley P, Snape M, Plested E, Thompson B, Nuthall E, Omar O . Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination. Arch Dis Child. 2013; 98(9):686-91. DOI: 10.1136/archdischild-2013-303893. View

14.

Miller E, Andrews N, Waight P, Slack M, George R . Herd immunity and serotype replacement 4 years after seven-valent pneumococcal conjugate vaccination in England and Wales: an observational cohort study. Lancet Infect Dis. 2011; 11(10):760-8. DOI: 10.1016/S1473-3099(11)70090-1. View

15.

de Voer R, Mollema L, Schepp R, De Greeff S, van Gageldonk P, de Melker H . Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS One. 2010; 5(8):e12144. PMC: 2921331. DOI: 10.1371/journal.pone.0012144. View

16.

Tully J, Viner R, Coen P, Stuart J, Zambon M, Peckham C . Risk and protective factors for meningococcal disease in adolescents: matched cohort study. BMJ. 2006; 332(7539):445-50. PMC: 1382533. DOI: 10.1136/bmj.38725.728472.BE. View

17.

Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B . Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun Dis Intell Q Rep. 2005; 28 Suppl 2:vii-S116. View

18.

Chiappini E, Venturini E, Bonsignori F, Galli L, de Martino M . Serogroup C Neisseria meningitidis invasive infection: analysis of the possible vaccination strategies for a mass campaign. Acta Paediatr. 2010; 99(11):1609-14. DOI: 10.1111/j.1651-2227.2010.01908.x. View

19.

Kinlin L, Jamieson F, Brown E, Brown S, Rawte P, Dolman S . Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Vaccine. 2009; 27(11):1735-40. DOI: 10.1016/j.vaccine.2009.01.026. View

20.

de Voer R, van der Klis F, Schepp R, Rijkers G, Sanders E, Berbers G . Age-related immunity to meningococcal serogroup C vaccination: an increase in the persistence of IgG2 correlates with a decrease in the avidity of IgG. PLoS One. 2011; 6(8):e23497. PMC: 3160848. DOI: 10.1371/journal.pone.0023497. View